Segall Bryant & Hamill LLC Has $37.82 Million Position in Bio-Techne Co. (NASDAQ:TECH)

Segall Bryant & Hamill LLC lifted its holdings in Bio-Techne Co. (NASDAQ:TECH) by 9.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 525,009 shares of the biotechnology company’s stock after purchasing an additional 47,129 shares during the period. Segall Bryant & Hamill LLC’s holdings in Bio-Techne were worth $37,816,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Brooklyn Investment Group acquired a new position in shares of Bio-Techne during the third quarter worth approximately $39,000. UMB Bank n.a. increased its position in Bio-Techne by 46.4% during the fourth quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 168 shares during the period. Quest Partners LLC acquired a new position in Bio-Techne during the 3rd quarter valued at $43,000. MassMutual Private Wealth & Trust FSB boosted its holdings in Bio-Techne by 60.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 672 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 253 shares during the period. Finally, Versant Capital Management Inc grew its position in Bio-Techne by 35.0% in the 4th quarter. Versant Capital Management Inc now owns 763 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 198 shares during the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Insider Buying and Selling

In other Bio-Techne news, CEO Kim Kelderman sold 13,392 shares of the business’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $77.29, for a total value of $1,035,067.68. Following the transaction, the chief executive officer now owns 39,004 shares of the company’s stock, valued at approximately $3,014,619.16. The trade was a 25.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Amy E. Herr sold 1,860 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $65.96, for a total value of $122,685.60. Following the completion of the sale, the director now owns 1,976 shares of the company’s stock, valued at approximately $130,336.96. This trade represents a 48.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.90% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Baird R W lowered shares of Bio-Techne from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Scotiabank raised their price objective on Bio-Techne from $88.00 to $90.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 6th. KeyCorp lifted their price objective on Bio-Techne from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Royal Bank of Canada upped their target price on Bio-Techne from $79.00 to $80.00 and gave the company a “sector perform” rating in a research note on Thursday, February 6th. Finally, Robert W. Baird downgraded shares of Bio-Techne from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $88.00 to $68.00 in a research note on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $81.25.

Bio-Techne Stock Performance

Bio-Techne stock opened at $61.07 on Tuesday. Bio-Techne Co. has a 52-week low of $56.60 and a 52-week high of $85.57. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.94 and a quick ratio of 2.77. The stock has a fifty day moving average price of $67.84 and a two-hundred day moving average price of $71.81. The firm has a market capitalization of $9.65 billion, a P/E ratio of 61.69, a P/E/G ratio of 2.88 and a beta of 1.30.

Bio-Techne (NASDAQ:TECH) last announced its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%. As a group, analysts anticipate that Bio-Techne Co. will post 1.67 EPS for the current fiscal year.

Bio-Techne Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, February 28th. Stockholders of record on Monday, February 17th were issued a $0.08 dividend. This represents a $0.32 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend was Friday, February 14th. Bio-Techne’s payout ratio is currently 32.32%.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.